Publication | Closed Access

Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model

Tumor ImmunologyCancer ImmunosurveillanceAdjuvant ImmunotherapyImmunologyTherapeutic VaccineMurine Adenocarcinoma ModelImmunomodulationImmunotherapyMedicineCell BiologyInterleukin 12